Efficacy of Montelukast on STEMl Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 512 participants.

Also called NCT07320625

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 512 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07320625
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07320625. Randomized; triple masking; primary purpose treatment. Start 2026-02-01 (anticipated); primary completion 2027-02-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Montelukast on STEMl Patients
Condition
Myocardial Infarction (MI)
Intervention (Drug)
Montelukast
Intervention (Drug)
Placebo
Lead sponsor
Shanghai Zhongshan Hospital (class: other)

Record details

Record id
cardio:ct-nct07320625
Content hash
151ba0bc67d573c196643430451b565e6cc1d4314abf4203555cf1eaaaf5031c